Half-Year Report
Half-Year Report
Sydney, Mar 1, 2019 AEST (ABN Newswire) - Regeneus (ASX:RGS) is an ASX-listed clinical-stage regenerative medicine company developing a portfolio of novel cell-based therapies targeting significant unmet medical needs in human and animal health, with an initial focus on osteoarthritis (OA), neuropathic pain and dermatology. The Company's product pipeline is underpinned by proprietary stem cell technologies.

Our strategy is to unlock value in our clinical-stage human pipeline products through developing novel and scalable technology product platforms underpinned by registered intellectual property; generating positive clinical data; and licensing to commercial partners at the optimal value inflection point. As these patented technologies have broad application, the Company has the opportunity to license the manufacturing and clinical development and commercialisation rights for a range of therapeutic indications in multiple territories, generating significant revenue streams.

To view the full report, please visit:

About Regeneus Ltd

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address significant unmet medical needs in the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain and dermatology.



Sandra McIntosh
Company Secretary and Investor Relations
Regeneus Ltd
T: +61-2-9499-8010
E: investors@regeneus.com.au

Daniel Paperny
Media and Capital Partners
T: +61-433-339454
E: Daniel.paperny@mcpartners.com.au

Related Companies

Regeneus Ltd      

ABN Newswire This Page Viewed:  (Last 7 Days: 17) (Last 30 Days: 77) (Since Published: 3589)